Published in BMJ Open Diabetes Res Care on December 12, 2016
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA (2015) 5.23
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ (2010) 4.92
Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol (2015) 4.87
Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol (2014) 4.67
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med (2016) 4.52
Epidemiologic association between prostatitis and prostate cancer. Urology (2002) 2.05
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care (2011) 1.83
Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health (2009) 1.74
Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care (2011) 1.47
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men. Br J Cancer (1988) 1.32
Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis (2012) 1.28
Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br J Cancer (2010) 1.24
Meta-analysis for combining relative risks of alcohol consumption and prostate cancer. Prostate (2000) 1.12
Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab (2013) 1.11
Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab (2013) 1.05
Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom. Eur J Cancer (2007) 1.03
Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev (2003) 1.02
Association of vasectomy and prostate cancer among men in a Maryland cohort. Cancer Causes Control (2005) 1.00
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig (2013) 0.98
Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev (2014) 0.98
Ethnic differences in prostate cancer. Br J Cancer (2011) 0.96
Cancer incidence in type 2 diabetes patients - first results from a feasibility study of the D2C cohort. Diabetol Metab Syndr (2011) 0.94
Alcohol and prostate cancer. Epidemiol Rev (2001) 0.94
Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer (2004) 0.90
Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab (2016) 0.84
Is there a link between BPH and prostate cancer? Practitioner (2012) 0.84
Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer. PPAR Res (2008) 0.83
Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012. Cancer Epidemiol Biomarkers Prev (2015) 0.80
Testosterone Replacement Therapy on the Natural History of Prostate Disease. Curr Urol Rep (2015) 0.78
Testosterone Replacement Therapy and Prostate Cancer Incidence. World J Mens Health (2015) 0.77